Search research articles
Contact Us
Filters
Showing results (1-10 of 6) with videos related to
Page
of 1
Sort By:
Journal of Pediatric Gastroenterology and Nutrition
|
December 21, 2012
US perspective on off-label use in pediatrics
Alyson Karesh, Andrew E Mulberg
Current Opinion in Pediatrics
|
September 3, 2013
Off-label use of medicine in pediatrics: focus on gastrointestinal diseases
Alyson Karesh, Juli Tomaino, Andrew E Mulberg
JAMA Pediatrics
|
August 8, 2013
Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007
Jeremiah D Momper, Yeruk Mulugeta, Dionna J Green, et al.
Journal of Clinical Pharmacology
|
June 13, 2014
Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design
Jeremiah D Momper, Alyson Karesh, Dionna J Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2017
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections
Janice Kim, Harpreet Singh, Kassa Ayalew, et al.
JAMA Network Open
|
June 17, 2025
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration
Donna R Rivera, Tracy L Cutler, Lisa McShane, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 6) with videos related to
Sort By:
Page
of 1
Journal of Pediatric Gastroenterology and Nutrition
|
December 21, 2012
US perspective on off-label use in pediatrics
Alyson Karesh, Andrew E Mulberg
Current Opinion in Pediatrics
|
September 3, 2013
Off-label use of medicine in pediatrics: focus on gastrointestinal diseases
Alyson Karesh, Juli Tomaino, Andrew E Mulberg
JAMA Pediatrics
|
August 8, 2013
Adolescent dosing and labeling since the Food and Drug Administration Amendments Act of 2007
Jeremiah D Momper, Yeruk Mulugeta, Dionna J Green, et al.
Journal of Clinical Pharmacology
|
June 13, 2014
Drug development for pediatric neurogenic bladder dysfunction: dosing, endpoints, and study design
Jeremiah D Momper, Alyson Karesh, Dionna J Green, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 15, 2017
Use of PRO Measures to Inform Tolerability in Oncology Trials: Implications for Clinical Review, IND Safety Reporting, and Clinical Site Inspections
Janice Kim, Harpreet Singh, Kassa Ayalew, et al.
JAMA Network Open
|
June 17, 2025
Modernizing Research and Evidence Consensus Definitions: A Food and Drug Administration-National Institutes of Health Collaboration
Donna R Rivera, Tracy L Cutler, Lisa McShane, et al.
Page
of 1